Methadone/Buprenorphine Cross-Over Study - 4
Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on December 31, 2007
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Opioid-Related Disorders
Intervention: Buprenorphine (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s):
Walter Ling, M.D., Principal Investigator, Affiliation: Friends Research Institute
Summary
The purpose of this study is to explore ways to cross patients over from methadone to
buprenorphine.
Clinical Details
Official title: Methadone/Buprenorphine Cross-Over Study
Study design: Treatment, Open Label
Primary outcome: Drug useWithdrawal symptoms Opiate craving
Eligibility
Minimum age: 21 Years.
Maximum age: 50 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
M/F ages 21-50. Opiate dependence according to DSM-IV critera. Self-reported use within the
last 30 days. Agreeable to conditions of study and signed informed consent.
Exclusion Criteria:
Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or
nursing women. Dependence on ETOH or benzodiazepines or other sedative-hynotics. Acute
hepatitis. Other medical conditions that deem participation to be unsafe.
Locations and Contacts
Friends Research Institute, Los Angeles, California 90025, United States
Additional Information
Starting date: February 1992
Last updated: August 16, 2005
|
